Skip to main
OBIO

OBIO Stock Forecast & Price Target

OBIO Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 29%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Orchestra BioMed Hldgs is currently in a favorable financial position with a strong cash runway into the fourth quarter of 2027, thanks in part to recent strategic capital investments from Medtronic and Ligand. The company's two flagship products, BackBeat CNT and Virtue SAB, have the potential to address large and underserved markets in cardiovascular diseases, with potential revenue opportunities of $100 million and $15 billion, respectively. Favorable results from upcoming clinical trials and potential future label expansions for AVIM Therapy could accelerate revenue growth and market adoption, making this stock a compelling buy opportunity.

Bears say

Orchestra BioMed Hldgs is a biomedical company with promising flagship product candidates but has a risky business model of relying on risk-reward sharing partnerships with medical device companies. The revenue outlook is heavily dependent on the successful commercialization of AVIM therapy and Virtue SAB in the US, with high projected CAGR but potential uncertainties in market acceptance and competition. Additionally, the company's current financial position relies heavily on strategic capital and milestone payments, and there may be potential dilution from future M&A activities. Overall, the company's future success is uncertain and may not align with current projections, leading to a negative outlook for its stock.

OBIO has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 29% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Orchestra BioMed Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Orchestra BioMed Holdings Inc (OBIO) Forecast

Analysts have given OBIO a Strong Buy based on their latest research and market trends.

According to 7 analysts, OBIO has a Strong Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Orchestra BioMed Holdings Inc (OBIO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.